Edwards Lifesciences price target lowered to $90 from $101 at Barclays

Barclays lowered the firm’s price target on Edwards Lifesciences to $90 from $101 and keeps an Overweight rating on the shares. Mgmt attributed the Q2 shortfall in transcatheter aortic valve replacement sales to reduced center capacity due to greater adoption of new structural heart therapies such as Evoque and TriClip, the analyst tells investors in a research note. The firm would view any significant weakness in the stock as a buying opportunity.